Pharmaceuticals company Sai Life Science announced Q4FY25 & FY25 results Q4FY25 Financial Highlights: Revenue from Operations was Rs 580 crore for Q4FY25 compared to Rs 439 crore in Q4FY24, an increase of 32% EBITDA stood at Rs 161 crore. for Q4FY25 compared to Rs 124 crore. in Q4FY24, an increase of 30% PAT stood at Rs 88 crore. for Q4FY25 compared to Rs 56 crore. in Q4FY24, an increase of 57% FY25 Financial Highlights: Revenue from Operations was Rs 1,695 crore for FY25 compared to Rs 1,465 crore in FY24, an increase of 16% EBITDA stood at Rs 425 crore. for FY25 compared to Rs 300 crore in FY24. an increase of 42% PAT stood at Rs 170crore. for FY25 compared to Rs 83 crore in FY24, an increase of 105% Commenting on the performance during the quarter, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said, “We are pleased to report a strong performance for FY25, ably supported by solid execution, capacity expansion, and deeper engagement with our customers. Our integrated CRDMO model continues to add value, helping us deliver seamless solutions across the drug development lifecycle to our global and biotech partners. One of the highlights of the year was the launch of our Peptide Research Centre, set up to meet the growing demand for complex peptide synthesis and conjugation. This investment marks another step forward in strengthening our capabilities to support next-generation therapeutics. With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. We remain focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of our clients. As we step into FY26, our priorities remain clear - to expand our capabilities, improve execution, and deliver lasting value to our stakeholders.” Siva Chittor, Director and Chief Financial Officer, Sai Life Sciences added, ” We are pleased to report a strong FY25 performance, driven by consistent momentum across our CDMO and CRO segments. Revenue grew by 16% and our EBITDA margin expanded to 25%, in line with our growth aspirations. Profit after tax grew by 105%, supported by stable finance costs and operating leverage. With the completion of our planned Rs 720 crore debt repayment, we have significantly strengthened our balance sheet and expect lower interest costs starting FY26. Capex for the year stood at Rs 408 crore, focused on enhancing our manufacturing footprint and expanding discovery capabilities. We remain committed to disciplined execution and prudent capital allocation as we continue to build on our growth momentum and deliver long-term value to stakeholders.” Result PDF
Pharmaceuticals company Sai Life Science announced Q3FY25 results Revenue from Operations was Rs 439.8 crore for Q3FY25 compared to Rs 383.6 crore in Q3FY24, an increase of 14.6%. EBITDA stood at Rs 124.5 crore for Q3FY25 compared to Rs 104.2 crore in Q3FY24 an increase of 19.5%. PAT stood at Rs 53.9 crore for Q3FY25 compared to Rs 39.6 crore in Q3FY24, an increase of 36.0%. Krishna Kanumuri, Managing Director & CEO, Sai Life Sciences, said: “We are pleased to announce a healthy performance this quarter, driven by strong execution, expanding capacity, and deepening customer relationships. Our integrated CRDMO model continues to differentiate us in the market, enabling us to provide seamless solutions across the drug development lifecycle. The pharmaceutical and biotech industries are increasingly seeking partners with end-to-end capabilities, scientific excellence, and a commitment to speed and efficiency areas where Sai Life Sciences has built a strong competitive edge. The global CRDMO industry presents a tremendous growth opportunity, particularly as large pharmaceutical and biotech companies diversify their supply chains and seek strategic partners beyond China. India is at the forefront of this transformation, with the potential to scale as a global innovation hub. With a robust pipeline of commercial molecules, a growing presence in key global markets, and continuous investments in technology and infrastructure, Sai Life Sciences is well-positioned to capitalize on these industry tailwinds. As we look ahead, we remain focused on strengthening our service offerings, expanding our capabilities into new modalities, and driving operational excellence. Our unwavering commitment to innovation, quality, and customercentricity will continue to propel us forward, delivering sustainable value to all our stakeholders.” Siva Chittor, Chief Financial Officer, Sai Life Sciences, said:” We are delighted to share our Q3 FY25 financial performance, which highlights robust business momentum, operational discipline, and strong customer relationships. Revenue from operations grew to Rs 439.8 crore, up 15% from Rs 383.6 crore in Q3FY24, on account of continued momentum in both our CDMO and CRO businesses. Our EBITDA margin increased to 28.3% in Q3FY25, up from 27.5% in Q3FY24, reflecting improved operating leverage and enhanced productivity. PAT grew to Rs 53.9 crore, compared to Rs 39.6 crore in Q3FY24, highlighting that our operational strategies are delivering results and positioning the company for sustained financial strength. This success is driven by disciplined cost management despite rising employee costs in line with our ongoing investment in talent and organizational growth. Finance costs remained relatively stable at Rs 23.1 crore for Q3FY25, compared to Rs 23.3 crore in the same quarter last year, indicating effective debt management. As of December 2024, the Company had repaid Rs 585.7 crore of debt out of the planned Rs 720.0 crore from the IPO proceeds. The remaining debt was repaid in January, and we expect a reduction in interest costs in the following quarter. We remain focused on investing in digital initiatives, new technologies, and commercial capabilities to fuel future growth. Over the past five years, our strategic investments in talent, technology, and infrastructure have strengthened our position as a leading integrated CRDMO player. These investments are now translating into higher customer retention, an expanding product pipeline, and improving profitability. Looking ahead, we expect sustained growth momentum, supported by a strong order pipeline and ongoing investments in infrastructure and capabilities.” Result PDF